Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
S Knipp, N Gattermann, M Schapira, H Käferstein… - Leukemia research, 2007 - Elsevier
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL)
included meningeal infiltration. Since he had previously experienced ATRA syndrome, he
received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and
methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF).
Arsenic showed a peak CSF concentration of 0.008 mg/l (0.11 μmol/l) and a nadir of 0.002
mg/l (0.027 μmol/l), both representing about 14% of blood levels. ATO thus crosses the …
included meningeal infiltration. Since he had previously experienced ATRA syndrome, he
received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and
methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF).
Arsenic showed a peak CSF concentration of 0.008 mg/l (0.11 μmol/l) and a nadir of 0.002
mg/l (0.027 μmol/l), both representing about 14% of blood levels. ATO thus crosses the …